GlassScriptPhysician profile
Thomas Fandel
NPI 1952833931
$10,587.01
in general payments reported to CMS, 2019-2025
46 companies · $3,388 in 2025
The $3,388 reported for 2025 was more than what 84% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,800 · 2023: $3,022 · 2024: $2,377 · 2025: $3,388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,777 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,776.80 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,923.44 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,347.70 | 2022-2025 | Mounjaro, Zepbound, Trulicity |
| Xeris Pharmaceuticals, INC. | $1,030.89 | 2022-2025 | Recorlev, Gvoke Hypopen |
| Amgen INC. | $797.03 | 2022-2025 | Tepezza, Evenity, Prolia |
| Mannkind Corporation | $554.12 | 2022-2025 | Afrezza |
| Sanofi-Aventis U.S. LLC | $351.55 | 2022-2025 | |
| Radius Health, INC. | $339.11 | 2022-2025 | Tymlos |
| Bayer Healthcare Pharmaceuticals INC. | $331.65 | 2022-2025 | |
| Pfizer INC. | $330.24 | 2022-2025 | |
| Madrigal Pharmaceuticals | $329.16 | 2025 | Rezdiffra |
| Aurinia Pharma U.S., INC. | $326.60 | 2022-2025 | Lupkynis |
| Ibsa Pharma INC. | $285.30 | 2022-2025 | Tirosint, Tirosint, Licart |
| Beta Bionics, INC. | $228.49 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Dexcom, INC. | $213.91 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $202.57 | 2022-2023 | Saphnelo, Farxiga |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $186.21 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $177.84 | 2022-2024 | Jardiance |
| Corcept Therapeutics | $165.15 | 2023-2024 | Korlym |
| Alexion Pharmaceuticals, INC. | $149.00 | 2022-2025 | Strensiq |
| Recordati_rare_diseases_inc. | $143.07 | 2023-2025 | Isturisa, Signifor Lar |
| Ascensia Diabetes Care US INC. | $134.61 | 2023 | |
| Janssen Biotech, INC. | $124.38 | 2022-2023 | Simponi Aria, Stelara, Simponi |
| Sequel Med Tech, LLC | $85.32 | 2025 | Twiist |
| Ascendis Pharma Endocrinology INC | $83.89 | 2025 | Yorvipath |
| Abbott Laboratories | $75.24 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Horizon Therapeutics Plc | $73.91 | 2022-2023 | Tepezza |
| Antares Pharma, INC. | $65.73 | 2023 | Tlando, Xyosted, Nocdurna |
| Ultragenyx Pharmaceutical INC. | $62.87 | 2022-2023 | |
| Almatica Pharma LLC | $60.82 | 2024-2025 | Teriparatide |
| Embecta Corp. | $39.16 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Organon LLC | $32.47 | 2025 | |
| Verity Pharmaceuticals INC. | $30.00 | 2025 | Tlando |
| Tolmar Pharmaceuticals, INC. | $26.16 | 2022 | |
| Eisai INC. | $26.11 | 2023 | |
| Fresenius Kabi USA, LLC | $25.47 | 2024 | Idacio |
| Sanofi Pasteur INC. | $25.43 | 2024 | |
| Chiesi USA, INC. | $25.09 | 2025 | Mycapssa |
| Tempus Ai, INC | $24.30 | 2025 | Xt Cdx |
| Kyowa Kirin, INC. | $23.02 | 2024 | Crysvita |
| Abbvie INC. | $22.67 | 2024 | |
| Esperion Therapeutics, INC. | $18.74 | 2025 | Nexletol |
| Merck Sharp & Dohme LLC | $18.42 | 2022 | |
| Cequr Corporation | $18.35 | 2023 | Cequr Simplicity |
| Regeneron Healthcare Solutions, INC. | $17.81 | 2024 | Evkeeza |
| Exact Sciences Corporation | $17.29 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $16.72 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Fandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.